YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.01 | 0.04 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 0.00 | 0.00 | -8.50 | -9.25 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -16.28% | -7.29% |
| Gross Margin | 0.00% | 0.00% | 25.39% | 79.31% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 8,326,612.16% | 8,182,751.22% | 8,240,870.97% | 8,696,113.02% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -2.16 | -4.59 |
| Interest Coverage | 0.00 | 0.00 | -7.66 | -10.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.49 | 0.18 |
| Cash Conversion Cycle | 0.00 | 0.00 | 417.17 | 678.88 |